Table 3 |
|
| Details of systemic chemotherapy | |
| Patients who received chemotherapy | |
| (n = 38 patients undergoing 56 resections) | |
| Timing of treatment | |
| Chemotherapy plus targeted agent | n = 11 resections (in 9 patients) |
| Neoadjuvant plus adjuvant | 7 (64%) |
| Neoadjuvant alone | 4 (36%) |
| Adjuvant alone | 0 |
| Chemotherapy alone | n = 38 resections (in 29 patients) |
| Neoadjuvant plus adjuvant | 15 (39%) |
| Neoadjuvant alone | 13 (34%) |
| Adjuvant alone | 10 (26%) |
| None* | n = 7 resections |
| Type of systemic treatment | |
| Targeted agents | n = 11 resections (in 9 patients) |
| Bevacizumab | 8 |
| Cetuximab | 2 |
| Sunitinib | 1 |
| Chemotherapy alone | n = 38 resections (in 29 patients) |
| Oxaliplatin | 22 |
| Irinotecan | 6 |
| Mitomycin | 5 |
| 5FU/Cape alone | 5 |
| Number of cycles | Median (range) |
| Pre-operative | 4 (2–12) |
| Targeted agents | 6 (4–12) |
| Chemo alone | 4 (2–8) |
| Post-operative | 5 (2–12) |
| Targeted agents | 6 (4–12) |
| Chemo alone | 4 (2–12) |
| Chemotherapy-related complications | |
| Pre-operative | 9 events (8 patients) |
| G3/4 neutropenia | 2 |
| G3/4 Thrombocytopenia | 1 |
| ≥G2 neuropathy | 2 |
| G3/4 diarrhoea | 1 |
| G3/4 Chest pain | 2 |
| G3 VTE (DVT) | 1 |
| Post-operative | 19 events (14 patients) |
| G3/4 neutropenia | 4 |
| G3/4 Thrombocytopenia | 1 |
| ≥G2 neuropathy | 3 |
| G3/4 diarrhoea | 3 |
| G3 fatigue | 2 |
| G3 infection | 1 |
| G3 GI bleed | 1 |
| G3 PPE | 1 |
| G3 stomatitis | 1 |
| G3 nausea | 1 |
| VTE (pulmonary embolism) | 1 |
Numbers in table refer to number of resections unless otherwise specified.
*7 resections occurred where patients received no chemotherapy, but had received for a prior or subsequent resection.
VTE venous thromboembolism, DVT deep vein thrombosis.
Hawkes et al. BMC Cancer 2012 12:326 doi:10.1186/1471-2407-12-326
